ImageneBio, Inc. (IMA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Current obligations | 6.57M USD | Liabilities, Current |
| Cash and equivalents | 94.68M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 41.48M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $6.57M | $94.68M | $41.48M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $6.63M | $76.05M | $41.16M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $11.23M | $94.53M | $40.82M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $11.14M | $103.16M | $39.42M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $7.32M | $58.29M | $37.35M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $8.79M | $36.76M | $77.29M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $10.78M | $39.39M | $84.99M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $9.24M | $45.19M | $92.84M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $8.20M | $44.27M | $101.15M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $10.17M | $52.85M | $104.50M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $14.21M | $119.89M | $55.57M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $19.27M | $121.28M | $75.66M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $12.01M | $70.87M | $86.44M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $13.95M | $29.33M | $108.48M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $21.50M | $59.92M | $97.03M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $25.04M | $67.07M | $107.29M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $28.51M | $48.49M | $144.32M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $25.33M | $46.88M | $165.50M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $27.19M | $232.22M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $30.57M | $245.90M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $30.54M | $264.00M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $30.02M | $281.01M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $28.33M | $162.49M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $55.86M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $63.53M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $72.11M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |